Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc.
TypePublic
IndustryPharmaceutical
Founded2002 (2002)
HeadquartersCambridge, Massachusetts, U.S.
Key people
RevenueIncrease US$3.71 billion (2025)
Increase US$502 million (2025)
Increase US$314 million (2025)
Total assetsIncrease US$4.97 billion (2025)
Total equityIncrease US$789 million (2025)
Number of employees
2,500 (2025)
Websitealnylam.com
Footnotes

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.